Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Recursion Pharmaceuticals

< Previous 1 2 Next >
Recursion Publishes Annual Environmental, Social and Governance Report
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Host Public L(earnings) Call on February 27
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Altitude Lab Startups Raise Over $120M in Capital
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Bayer and Recursion Focus Research Collaboration on Oncology
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Tickers RXRX
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Publishes Second Annual Environmental, Social and Governance Report
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.